ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome

07 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022

17 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy

21 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease

23 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results

09 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022

02 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

21 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

08 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

19 May 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

10 May 2022 07:00:02 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

27 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

26 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

07 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit

28 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference

15 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum

09 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

04 Mar 2022 07:00:00 By Nasdaq GlobeNewswire